Synopsis

Source of validity: Scientific
Rating (out of 5): 3

Butyrate triglyceride, as a form of butyrate delivery, has a scientific rationale for use in supporting or treating Inflammatory Bowel Disorders (IBD), particularly ulcerative colitis and Crohn’s disease. Butyrate is a short-chain fatty acid (SCFA) produced by microbial fermentation of dietary fibers in the colon, and it serves as the primary energy source for colonocytes. Research has shown that butyrate possesses anti-inflammatory, immunomodulatory, and epithelial barrier-enhancing effects. In patients with IBD, endogenous butyrate production is often reduced due to dysbiosis, leading to compromised colonic health. Clinical studies (mainly small-scale trials and pilot studies) have investigated oral or rectal administration of butyrate or butyrate-releasing formulations (including butyrate triglyceride). These studies suggest some benefit in reducing inflammation and improving symptoms, especially in mild to moderate ulcerative colitis. Mechanistically, butyrate inhibits nuclear factor kappa B (NF-κB) activation, reduces pro-inflammatory cytokine production, and promotes regulatory T-cell differentiation, all of which contribute to mucosal healing. However, the overall quality and quantity of clinical evidence remain moderate, with larger randomized controlled trials still needed. Most guidelines do not yet recommend butyrate as standard therapy, but it is considered promising as an adjunct. Butyrate triglyceride is used to improve palatability, absorption, and targeted delivery, but direct evidence for its efficacy, as opposed to other butyrate formulations, is still evolving.

More about butyrate triglyceride
More about Inflammatory Bowel Disorders

Other ingredients used for Inflammatory Bowel Disorders

Other health conditions supported by butyrate triglyceride

Products containing butyrate triglyceride

Douglas Laboratories MCT/Butyrate Liquid with SunButyrate™
Pure Encapsulations SunButyrate-TG